ImmuCell Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2012; filed November 13, 2012. ImmuCell develops, manufactures, and sells animal-health products, primarily for the dairy and beef industries, and is developing Mast Out, a treatment for subclinical mastitis.
Financial results and position
- Revenue: Product sales were $1.077 million for Q3 2012, up 7% from $1.003 million; nine-month sales were $3.969 million, up 4% from $3.807 million. Management attributed some year-to-date growth to approximately $116,000 of bulk-reagent sales not recorded in the comparable 2011 period. First Defense, the lead product, had nine-month sales growth of 2%.
- Margins: Gross margin was $621,000 in Q3 and $2.304 million for the first nine months, versus $526,000 and $2.089 million, respectively. Gross margin as a percentage of sales improved to 58% from 52% for Q3 and to 58% from 55% year to date.
- Profitability: Q3 operating loss was $86,000 and net loss was $64,000 ($0.02 per share), compared with operating loss of $192,000 and net loss of $128,000 ($0.04 per share) in Q3 2011. For the first nine months, operating income was $233,000 and net income was $106,000 ($0.03 diluted per share), versus operating loss of $642,000 and net loss of $409,000 ($0.14 per share) in 2011. Lower product-development spending, particularly on Mast Out, and improved First Defense gross margin drove the year-to-date improvement.
- Cash flow: Nine-month operating cash flow was positive $181,000, compared with cash used of $332,000 in 2011. Capital expenditures were $250,000. Cash and equivalents increased to $1.585 million from $782,000; net cash provided by investing activities was $693,000, while financing used $71,000.
- Liquidity and debt: Cash, equivalents, and short-term investments totaled $4.820 million, down from $4.960 million at year-end 2011. Working capital was $6.719 million, versus $6.516 million. Total debt principal outstanding was $1.312 million; the $500,000 credit line was available as needed. Debt is secured by substantially all assets. The company reported covenant compliance and a requirement to maintain at least $1 million in qualifying liquid funds.
- Balance sheet: Total assets were $10.971 million, total liabilities $1.772 million, and stockholders’ equity $9.199 million at September 30, 2012. Inventory was $1.800 million. A $451,885 mortgage balloon payment is due in 2020.
Material changes and business developments
- Product-development expense fell 53% year to date to $683,000, primarily because major Mast Out clinical studies were largely complete. Sales and marketing expense rose 8% to $687,000 year to date, reflecting planned investment; administrative expense increased 8% to $701,000.
- Domestic sales increased approximately 1% and international sales 21% in the first nine months. International sales represented 16% of year-to-date sales. Two distributors accounted for 35% and 14% of nine-month sales, indicating material customer concentration.
- Management described difficult selling conditions for calf-health products, including mild spring weather, high feed costs, distributor consolidation, and competition. First Defense sales are seasonal, typically stronger in the first quarter.
Outlook, risks, and contingencies
- Management expected approximately $175,000 of net income for full-year 2012 and stated it believed resources were sufficient for working capital and operations for at least 12 months. These are forward-looking estimates, not guarantees.
- Management revised its Mast Out active pharmaceutical ingredient manufacturing plan from building a new facility to leasing and equipping an existing one, estimating investment of approximately $6 million. It said most initial-launch capital was available internally and that a modest amount of debt might cover any shortfall if more favorable financing was unavailable; it continued to seek a marketing partner. The filing also cites an earlier estimated $13 million completion-and-launch budget under the prior plan.
- Mast Out still required FDA approval. The filing reported completed FDA technical-section letters for environmental impact, target-animal safety, and effectiveness. The human-food-safety section had received acceptance of key subsections, including zero milk-discard and zero meat-withhold periods; the company was working toward a complete-letter review. The CMC section had been withdrawn for revision following changes to its regulatory and manufacturing strategy. Management described facility work, review timing, and regulatory milestones as planned or anticipated, not completed approvals.
- Key risks include failure or delay in FDA approval, manufacturing and financing execution, market acceptance and pricing, possible effects on cultured dairy products, reliance on First Defense and a small number of distributors, dairy/beef economics and feed costs, raw-material supply, and dependence on key employees and manufacturing facilities. International approval may not permit Mast Out’s zero-discard claim.
- The company reported no legal proceedings, no defaults, and no material changes in internal controls. Management concluded disclosure controls were effective at quarter-end.
Important facts for investors to verify
- Current Mast Out FDA review status, including completion of the human-food-safety and CMC sections and any subsequent approval milestones.
- Actual costs, timing, financing, and regulatory readiness of the leased API facility compared with the stated approximately $6 million estimate.
- Full-year 2012 earnings versus management’s approximately $175,000 expectation, and whether gross margins and operating income remain sustainable.
- First Defense sales trends, distributor concentration and ordering patterns, and the impact of dairy-sector conditions on demand.
- Liquidity, debt-covenant compliance, and available funding as Mast Out development and commercialization spending proceeds.